Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Multiple Routes to Oncogenesis are Promoted by the Human Papillomavirus-Host Protein Network.

Eckhardt M, Zhang W, Gross AM, Von Dollen J, Johnson JR, Franks-Skiba KE, Swaney DL, Johnson TL, Jang GM, Shah PS, Brand TM, Archambault J, Kreisberg JF, Grandis JR, Ideker T, Krogan NJ.

Cancer Discov. 2018 Sep 12. pii: CD-17-1018. doi: 10.1158/2159-8290.CD-17-1018. [Epub ahead of print]

PMID:
30209081
2.

BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.

Leonard B, Brand TM, O'Keefe RA, Lee ED, Zeng Y, Kemmer JD, Li H, Grandis JR, Bhola NE.

Cancer Res. 2018 Aug 1;78(15):4331-4343. doi: 10.1158/0008-5472.CAN-18-0459. Epub 2018 May 23.

PMID:
29792310
3.

Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR.

Cancer Res. 2018 May 1;78(9):2383-2395. doi: 10.1158/0008-5472.CAN-17-1672. Epub 2018 Feb 12.

PMID:
29440171
4.

The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.

Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL.

Sci Signal. 2017 Jan 3;10(460). pii: eaag1064. doi: 10.1126/scisignal.aag1064.

PMID:
28049763
5.

Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.

Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR.

Clin Cancer Res. 2017 Jun 15;23(12):3072-3083. doi: 10.1158/1078-0432.CCR-16-2203. Epub 2016 Dec 16.

6.

Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.

Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran PJ, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL.

Mol Cancer Ther. 2016 Sep;15(9):2175-86. doi: 10.1158/1535-7163.MCT-16-0012. Epub 2016 Jul 15.

7.

Adaptive responses to antibody based therapy.

Rodems TS, Iida M, Brand TM, Pearson HE, Orbuch RA, Flanigan BG, Wheeler DL.

Semin Cell Dev Biol. 2016 Feb;50:153-63. doi: 10.1016/j.semcdb.2016.01.001. Epub 2016 Jan 22. Review.

PMID:
26808665
8.

AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL.

Clin Cancer Res. 2015 Jun 1;21(11):2601-12. doi: 10.1158/1078-0432.CCR-14-2648. Epub 2015 Mar 12.

9.

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.

Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL.

Mol Cancer. 2014 Oct 24;13:242. doi: 10.1186/1476-4598-13-242.

10.

AXL mediates resistance to cetuximab therapy.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL.

Cancer Res. 2014 Sep 15;74(18):5152-64. doi: 10.1158/0008-5472.CAN-14-0294. Epub 2014 Aug 18.

11.

Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.

Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL.

Mol Cancer Ther. 2014 May;13(5):1356-68. doi: 10.1158/1535-7163.MCT-13-1021. Epub 2014 Mar 14.

12.

Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.

Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R.

Mol Cancer Ther. 2014 Mar;13(3):576-84. doi: 10.1158/1535-7163.MCT-13-0109. Epub 2013 Dec 10.

13.

Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.

Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M, Wheeler DL.

Neoplasia. 2013 Oct;15(10):1196-206.

14.
15.

Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3.

Brand TM, Iida M, Luthar N, Wleklinski MJ, Starr MM, Wheeler DL.

PLoS One. 2013 Aug 8;8(8):e71518. doi: 10.1371/journal.pone.0071518. eCollection 2013.

16.

Nuclear EGFR as a molecular target in cancer.

Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL.

Radiother Oncol. 2013 Sep;108(3):370-7. doi: 10.1016/j.radonc.2013.06.010. Epub 2013 Jul 3. Review.

17.

Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer.

Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, Wheeler DL, Husain AN, Natarajan V, Vokes EE, Singleton PA, Salgia R.

Cancer Biol Ther. 2013 Jul;14(7):679-91. doi: 10.4161/cbt.25091. Epub 2013 May 31.

18.

Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab.

Iida M, Brand TM, Campbell DA, Starr MM, Luthar N, Traynor AM, Wheeler DL.

Cancer Biol Ther. 2013 Jun;14(6):481-91. doi: 10.4161/cbt.24342.

19.

Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.

Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand TM, Hoang T, Campbell TC, Hernan HR, Wheeler DL.

Lung Cancer. 2013 Jul;81(1):138-41. doi: 10.1016/j.lungcan.2013.03.020. Epub 2013 Apr 28.

20.

KRAS mutant colorectal tumors: past and present.

Brand TM, Wheeler DL.

Small GTPases. 2012 Jan-Mar;3(1):34-9. doi: 10.4161/sgtp.18751.

21.

Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.

Iida M, Brand TM, Campbell DA, Li C, Wheeler DL.

Oncogene. 2013 Feb 7;32(6):759-67. doi: 10.1038/onc.2012.90. Epub 2012 Mar 19.

22.

The nuclear epidermal growth factor receptor signaling network and its role in cancer.

Brand TM, Iida M, Li C, Wheeler DL.

Discov Med. 2011 Nov;12(66):419-32. Review.

23.

Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.

Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL.

Cancer Biol Ther. 2011 Sep 1;12(5):436-46. Epub 2011 Sep 1.

24.

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.

Brand TM, Iida M, Wheeler DL.

Cancer Biol Ther. 2011 May 1;11(9):777-92. Epub 2011 May 1. Review.

25.

Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate.

Brand TM, Wheeler DL.

Cancer Biol Ther. 2011 Feb 1;11(3):368-70. Epub 2011 Feb 1. No abstract available.

PMID:
21228636
26.

Mediastinal lymphadenopathy in patients undergoing cardiac transplant evaluation.

Pastis NJ Jr, Van Bakel AB, Brand TM, Ravenel JG, Gilbert GE, Silvestri GA, Judson MA.

Chest. 2011 Jun;139(6):1451-1457. doi: 10.1378/chest.10-1386. Epub 2010 Oct 21.

27.

Enamel nail polish does not interfere with pulse oximetry among normoxic volunteers.

Brand TM, Brand ME, Jay GD.

J Clin Monit Comput. 2002 Feb;17(2):93-6.

PMID:
12212998

Supplemental Content

Loading ...
Support Center